Literature DB >> 11474241

Clinicopathological study of early adenocarcinoma of the gastric cardia: comparison with early adenocarcinoma of the distal stomach and esophagus.

Y Tajima1, Y Nakanishi, T Yoshino, A Kokawa, M Kusano, T Shimoda.   

Abstract

To clarify the clinicopathological characteristics of adenocarcinoma of the gastric cardia (AGC), including its association with Barrett's esophagus and intestinal metaplasia, 49 surgically resected early AGCs (EAGCs) were examined clinicopathologically, histopathologically, histochemically, and immunohistochemically. The clinicopathological characteristics of the patients with EAGC were compared with those of 293 patients with early adenocarcinoma of the distal stomach (EADS) and 7 patients with early adenocarcinoma of the esophagus (EAE). Histochemical staining with paradoxical concanavalin A (ConA) and immunohistochemical staining with monoclonal antibodies 45M1, Ccp58, and 56C6 were performed to investigate the differentiation phenotype of the tumor. ConA and 45M1 were used for markers of the gastric phenotype, and Ccp58 and 56C6 were used for markers of the intestinal phenotype. EAGC was associated with a higher mean age (p < 0.0001), a higher male-to-female ratio (p < 0.05), a higher incidence of elevated-type tumors (p < 0.0001), a higher incidence of differentiated-type tumors (p < 0.0001), and greater depth of invasion (p < 0.05) compared with EADS. EAE was associated with a higher incidence of elevated-type tumors (p < 0.001), a higher incidence of differentiated-type tumors (p < 0.05), and larger tumor size (p < 0.05) compared with EADS. The prevalence of Barrett's esophagus in patients with EAGC was significantly lower than in patients with EAE (10.2%, 5/49 patients vs. 100%, 7/7; p < 0.0001). The prevalence of intestinal (Barrett's) metaplasia in surrounding non-neoplastic mucosa in patients with EAGC was significantly lower than in patients with EADS or EAE (36.7%, 18/49 patients vs. 72.0%, 211/293 and 85.7%, 6/7; p < 0.0001 and p < 0.05, respectively). EAGC was associated with a higher incidence of tumors that reacted positively for gastric phenotype markers alone than EADS (32.7%, 16/49 cases vs. 17.1%, 50/293; p < 0.05) and a lower incidence of tumors that reacted positively for both gastric and intestinal markers than EADS or EAE (40.8%, 20/49 cases vs. 59.7%, 175/293 and 85.7%, 6/7; p < 0.05, respectively). Our findings indicate that AGC forms a specific category different from both adenocarcinoma of the distal stomach and esophagus in terms of association with Barrett's esophagus or intestinal metaplasia, and the differentiation phenotype of the tumor. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474241     DOI: 10.1159/000055345

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  18 in total

1.  Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?

Authors:  Matthias Haas; Maike Büttner; Tilman T Rau; Rainer Fietkau; Gerhard G Grabenbauer; Luitpold V Distel
Journal:  Virchows Arch       Date:  2011-02-26       Impact factor: 4.064

2.  Combined Extensive Esophageal Squamous Papillomas and Florid Cardiac Gland Hyperplasia in a Patient with Adenocarcinoma.

Authors:  Takanori Suganuma; Han-Seung Yoon
Journal:  GE Port J Gastroenterol       Date:  2017-08-24

3.  Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract.

Authors:  Helene Geddert; Sibylle Kiel; Rainer B Zotz; Jianhui Zhang; Reinhart Willers; Helmut E Gabbert; Mario Sarbia
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-15       Impact factor: 4.553

Review 4.  Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach.

Authors:  Ryoji Kushima; Michael Vieth; Franz Borchard; Manfred Stolte; Ken-ichi Mukaisho; Takanori Hattori
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

5.  Treatment of oesophageal ulcerations using endoscopic transplantation of tissue-engineered autologous oral mucosal epithelial cell sheets in a canine model.

Authors:  T Ohki; M Yamato; D Murakami; R Takagi; J Yang; H Namiki; T Okano; K Takasaki
Journal:  Gut       Date:  2006-05-18       Impact factor: 23.059

6.  Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil.

Authors:  Yusuke Tajima; Tadakazu Shimoda; Yukihiro Nakanishi; Noboru Yokoyama; Takayuki Tanaka; Kouji Shimizu; Toyohiko Saito; Masatoshi Kawamura; Mitsuo Kusano; Kazuhide Kumagai
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-24       Impact factor: 4.553

7.  Genetic variants in fas signaling pathway genes and risk of gastric cancer.

Authors:  Paula L Hyland; Shih-Wen Lin; Nan Hu; Han Zhang; Lemin Wang; Hua Su; Chaoyu Wang; Ti Ding; Ze-Zhong Tang; Jin-Hu Fan; You-Lin Qiao; Xiaoqin Xiong; William Wheeler; Carol Giffen; Kai Yu; Jeff Yuenger; Laurie Burdett; Zhaoming Wang; Stephen J Chanock; Margaret A Tucker; Sanford M Dawsey; Neal D Freedman; Alisa M Goldstein; Christian C Abnet; Philip R Taylor
Journal:  Int J Cancer       Date:  2013-09-11       Impact factor: 7.396

8.  Association between gastric cardia adenocarcinoma risk and alcohol flushing response, but not alcohol consumption.

Authors:  Qingxu Song; Peng Hu; Jianbo Wang; Yibin Jia; Guangyu Zhang; Li Lv; Yuan Liu; Yufeng Cheng
Journal:  Med Oncol       Date:  2014-01-30       Impact factor: 3.064

Review 9.  Unique Clinicopathology of Proximal Gastric Carcinoma: A Critical Review.

Authors:  Qin Huang
Journal:  Gastrointest Tumors       Date:  2014-07-18

10.  Comparison of global gene expression of gastric cardia and noncardia cancers from a high-risk population in china.

Authors:  Gangshi Wang; Nan Hu; Howard H Yang; Lemin Wang; Hua Su; Chaoyu Wang; Robert Clifford; Erica M Dawsey; Jian-Min Li; Ti Ding; Xiao-You Han; Carol Giffen; Alisa M Goldstein; Philip R Taylor; Maxwell P Lee
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.